O	0	11	Comparative
O	12	25	effectiveness
O	26	28	of
B-intervention	29	32	MRI
O	33	35	in
O	36	42	breast
O	43	49	cancer
O	50	51	(
O	51	57	COMICE
O	57	58	)
O	59	64	trial
O	64	65	:
O	66	67	a
O	68	78	randomised
O	79	89	controlled
O	90	95	trial
O	95	96	.

O	97	100	MRI
O	101	106	might
O	107	114	improve
O	115	124	diagnosis
O	125	127	of
O	128	134	breast
O	135	141	cancer
O	141	142	,
O	143	151	reducing
O	152	157	rates
O	158	160	of
O	161	172	reoperation
O	172	173	.

O	174	176	We
O	177	185	assessed
O	186	189	the
O	190	198	clinical
O	199	207	efficacy
O	208	210	of
O	211	219	contrast
O	219	220	-
O	220	228	enhanced
O	229	232	MRI
O	233	235	in
B-eligibility	236	241	women
I-eligibility	242	246	with
I-eligibility	247	254	primary
I-eligibility	255	261	breast
I-eligibility	262	268	cancer
O	268	269	.

O	270	272	We
O	273	282	undertook
O	283	285	an
O	286	290	open
O	290	291	,
O	292	300	parallel
O	301	306	group
O	307	312	trial
O	313	315	in
O	316	318	45
B-location	319	321	UK
O	322	329	centres
O	329	330	,
O	331	335	with
B-total-participants	336	340	1623
O	341	346	women
O	347	351	aged
B-age	352	354	18
I-age	355	360	years
I-age	361	363	or
I-age	364	369	older
O	370	374	with
O	375	381	biopsy
O	381	382	-
O	382	388	proven
O	389	396	primary
O	397	403	breast
O	404	410	cancer
O	411	414	who
O	415	419	were
O	420	429	scheduled
O	430	433	for
O	434	438	wide
O	439	444	local
O	445	453	excision
O	454	459	after
O	460	466	triple
O	467	477	assessment
O	477	478	.

O	479	487	Patients
O	488	492	were
O	493	501	randomly
O	502	510	assigned
O	511	513	to
O	514	521	receive
O	522	528	either
O	529	532	MRI
O	533	534	(
O	534	535	n
O	535	536	=
B-intervention-participants	536	539	816
O	539	540	)
O	541	543	or
B-control	544	546	no
I-control	547	554	further
I-control	555	562	imaging
O	563	564	(
B-control-participants	564	567	807
O	567	568	)
O	568	569	,
O	570	574	with
O	575	578	use
O	579	581	of
O	582	583	a
O	584	596	minimisation
O	597	606	algorithm
O	607	620	incorporating
O	621	622	a
O	623	629	random
O	630	637	element
O	637	638	.

O	639	642	The
O	643	650	primary
O	651	659	endpoint
O	660	663	was
O	664	667	the
B-outcome-Measure	668	678	proportion
I-outcome-Measure	679	681	of
I-outcome-Measure	682	690	patients
I-outcome-Measure	691	701	undergoing
I-outcome-Measure	702	703	a
I-outcome-Measure	704	710	repeat
I-outcome-Measure	711	720	operation
I-outcome-Measure	721	723	or
I-outcome-Measure	724	731	further
I-outcome-Measure	732	742	mastectomy
I-outcome-Measure	743	749	within
I-outcome-Measure	750	751	6
I-outcome-Measure	752	758	months
I-outcome-Measure	759	761	of
I-outcome-Measure	762	768	random
I-outcome-Measure	769	779	assignment
I-outcome-Measure	779	780	,
I-outcome-Measure	781	783	or
I-outcome-Measure	784	785	a
I-outcome-Measure	786	800	pathologically
I-outcome-Measure	801	810	avoidable
I-outcome-Measure	811	821	mastectomy
I-outcome-Measure	822	824	at
I-outcome-Measure	825	832	initial
I-outcome-Measure	833	842	operation
O	842	843	.

O	844	852	Analysis
O	853	856	was
O	857	859	by
O	860	869	intention
O	870	872	to
O	873	878	treat
O	878	879	.

O	880	884	This
O	885	890	study
O	891	893	is
O	894	904	registered
O	904	905	,
O	906	912	ISRCTN
O	913	919	number
O	920	928	57474502
O	928	929	.

B-intervention-participants	930	933	816
O	934	942	patients
O	943	947	were
O	948	956	randomly
O	957	965	assigned
O	966	968	to
O	969	972	MRI
O	973	976	and
B-control-participants	977	980	807
O	981	983	to
B-control	984	986	no
I-control	987	990	MRI
O	990	991	.

O	992	1000	Addition
O	1001	1003	of
O	1004	1007	MRI
O	1008	1010	to
O	1011	1023	conventional
O	1024	1030	triple
O	1031	1041	assessment
O	1042	1045	was
O	1046	1049	not
O	1050	1063	significantly
O	1064	1074	associated
O	1075	1079	with
O	1080	1087	reduced
O	1088	1089	a
B-outcome	1090	1101	reoperation
I-outcome	1102	1106	rate
O	1106	1107	,
O	1108	1112	with
B-iv-bin-abs	1113	1116	153
O	1117	1118	(
B-iv-bin-percent	1118	1120	19
I-iv-bin-percent	1120	1121	%
O	1121	1122	)
O	1123	1130	needing
O	1131	1142	reoperation
O	1143	1145	in
O	1146	1149	the
O	1150	1153	MRI
O	1154	1159	group
O	1160	1166	versus
B-cv-bin-abs	1167	1170	156
O	1171	1172	(
B-cv-bin-percent	1172	1174	19
I-cv-bin-percent	1174	1175	%
O	1175	1176	)
O	1177	1179	in
O	1180	1183	the
O	1184	1186	no
O	1187	1190	MRI
O	1191	1196	group
O	1196	1197	,
O	1198	1199	(
O	1199	1203	odds
O	1204	1209	ratio
O	1210	1211	0
O	1211	1212	.
O	1212	1214	96
O	1214	1215	,
O	1216	1218	95
O	1218	1219	%
O	1220	1222	CI
O	1223	1224	0
O	1224	1225	.
O	1225	1227	75
O	1227	1228	-
O	1228	1229	1
O	1229	1230	.
O	1230	1232	24
O	1232	1233	;
O	1234	1235	p
O	1235	1236	=
O	1236	1237	0
O	1237	1238	.
O	1238	1240	77
O	1240	1241	)
O	1241	1242	.

O	1243	1246	Our
O	1247	1255	findings
O	1256	1259	are
O	1260	1262	of
O	1263	1270	benefit
O	1271	1273	to
O	1274	1277	the
O	1278	1281	NHS
O	1282	1289	because
O	1290	1294	they
O	1295	1299	show
O	1300	1304	that
O	1305	1308	MRI
O	1309	1314	might
O	1315	1317	be
O	1318	1329	unnecessary
O	1330	1332	in
O	1333	1337	this
O	1338	1348	population
O	1349	1351	of
O	1352	1360	patients
O	1361	1363	to
O	1364	1370	reduce
O	1371	1377	repeat
O	1378	1387	operation
O	1388	1393	rates
O	1393	1394	,
O	1395	1398	and
O	1399	1404	could
O	1405	1411	assist
O	1412	1414	in
O	1415	1423	improved
O	1424	1427	use
O	1428	1430	of
O	1431	1434	NHS
O	1435	1443	services
O	1443	1444	.

O	1445	1453	National
O	1454	1463	Institute
O	1464	1467	for
O	1468	1474	Health
O	1475	1483	Research
O	1483	1484	'
O	1484	1485	s
O	1486	1492	Health
O	1493	1503	Technology
O	1504	1514	Assessment
O	1515	1524	Programme
O	1524	1525	.
